Correlation Between IL-8, C-Reactive Proteins (CRP) and Neutrophil to Lymphocyte Ratio (NLR) as Predictor of Mortality in COVID-19 Patients with Diabetes Mellitus Comorbidity.
COVID-19
CRP
NLR
interleukin-8
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
03
2023
accepted:
16
05
2023
medline:
14
6
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
epublish
Résumé
COVID-19 is caused by SARS-CoV-2 and has a wide range of symptoms. While Diabetes Mellitus (DM) is a common comorbidity in COVID-19 patients, it is the main comorbidity in non-surviving COVID-19 patients. Interleukin-8 (IL-8) is a cytokine that has been correlated with severity and mortality in COVID-19 patients, but its role in COVID-19 patients with DM comorbidity and its relationship with NLR and CRP as markers of inflammation are not yet fully understood. To investigate the correlation between IL-8, NLR, and CRP in COVID-19 patients with DM comorbidity. A cross-sectional study was conducted at the Integrated Infectious Disease Installation of Dr. Saiful Anwar Malang Hospital from June to November 2021 using consecutive sampling. IL-8 was measured using the ELISA method with Legendmax A total of 124 research subjects participated in the study. IL-8 and CRP levels were significantly higher (p < 0.05) in COVID-19 patients with DM comorbidity, and were also significantly higher (p < 0.05) in non-surviving COVID-19 patients. Overall, there was a positive correlation between IL-8 and CRP (r = 0.58, p < 0.05). There was also a positive correlation between IL-8 (r = 0.58; p < 0.05), NLR (r = 0.45, p < 0.05), CRP (r = 0.54, p < 0.05) and mortality in COVID-19 patients with DM comorbidity. The presence of DM comorbidity increased IL-8 levels and aggravated inflammation in COVID-19 patients, thereby increasing the risk of mortality. IL-8, CRP and NLR levels were higher in non-surviving COVID-19 patients with DM comorbidity, indicating that they could serve as good predictors of poor outcomes in this patient population.
Sections du résumé
Background
UNASSIGNED
COVID-19 is caused by SARS-CoV-2 and has a wide range of symptoms. While Diabetes Mellitus (DM) is a common comorbidity in COVID-19 patients, it is the main comorbidity in non-surviving COVID-19 patients. Interleukin-8 (IL-8) is a cytokine that has been correlated with severity and mortality in COVID-19 patients, but its role in COVID-19 patients with DM comorbidity and its relationship with NLR and CRP as markers of inflammation are not yet fully understood.
Objective
UNASSIGNED
To investigate the correlation between IL-8, NLR, and CRP in COVID-19 patients with DM comorbidity.
Methods
UNASSIGNED
A cross-sectional study was conducted at the Integrated Infectious Disease Installation of Dr. Saiful Anwar Malang Hospital from June to November 2021 using consecutive sampling. IL-8 was measured using the ELISA method with Legendmax
Results
UNASSIGNED
A total of 124 research subjects participated in the study. IL-8 and CRP levels were significantly higher (p < 0.05) in COVID-19 patients with DM comorbidity, and were also significantly higher (p < 0.05) in non-surviving COVID-19 patients. Overall, there was a positive correlation between IL-8 and CRP (r = 0.58, p < 0.05). There was also a positive correlation between IL-8 (r = 0.58; p < 0.05), NLR (r = 0.45, p < 0.05), CRP (r = 0.54, p < 0.05) and mortality in COVID-19 patients with DM comorbidity. The presence of DM comorbidity increased IL-8 levels and aggravated inflammation in COVID-19 patients, thereby increasing the risk of mortality.
Conclusion
UNASSIGNED
IL-8, CRP and NLR levels were higher in non-surviving COVID-19 patients with DM comorbidity, indicating that they could serve as good predictors of poor outcomes in this patient population.
Identifiants
pubmed: 37313045
doi: 10.2147/IJGM.S412070
pii: 412070
pmc: PMC10259590
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2349-2354Informations de copyright
© 2023 Iskandar et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Int J Environ Res Public Health. 2022 May 27;19(11):
pubmed: 35682137
Medicine (Baltimore). 2021 Mar 19;100(11):e23656
pubmed: 33725924
J Immunol Res. 2019 Apr 10;2019:6252138
pubmed: 31093511
J Med Virol. 2020 Nov;92(11):2409-2411
pubmed: 32516845
Front Immunol. 2021 Jan 29;12:626235
pubmed: 33584733
World J Diabetes. 2020 Oct 15;11(10):468-480
pubmed: 33133394
BMC Infect Dis. 2021 Sep 6;21(1):921
pubmed: 34488665
Expert Rev Endocrinol Metab. 2022 Jan;17(1):83-93
pubmed: 34781810
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981
Int J Epidemiol. 2021 May 17;50(2):420-429
pubmed: 33683344
Prim Care Diabetes. 2022 Feb;16(1):65-68
pubmed: 34857490